Ocugen Inc (OCGN)

NASDAQ

$1.33

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the development of gene therapies to cure diseases of blindness. The company is headquartered in Malvern, Pennsylvania.

Website: https://www.ocugen.com

Sector:

Healthcare

Industry:

Biotechnology

68 analysts

Buy

Target: $11.43 (+759.40%)

Market Cap

$484M

Revenue 5Y CAGR

+153.09%

FCF 5Y CAGR

+30.37%

Free Cash Flow Yield

-12.31%

Price Chart

Adjust inflation

Log

Valuation

Market Cap$484M

Forward P/E13.07

P/S108.42

P/B83.39

Profitability

Total Revenue (TTM)$4.46M

Gross Profit (TTM)-$37M

EBITDA-$64M

Operating Margin-1164%

EPS-$0.23

Financial Health

Debt-to-Equity502.9%

Free Cash Flow Yield-12.31%

Growth & Risk

EPS 5Y CAGR+8.79%

Revenue 5Y CAGR+153.09%

FCF 5Y CAGR+30.37%

Beta (5Y)1.71

Sharpe Ratio0.70